Home / Biosimilars / News / Indian drugmakers make progress with candidate biosimilars
Indian drugmakers make progress with candidate biosimilars Posted 05/06/2015

India-based biologicals specialist Biocon announced on 7 May 2015 that it had made clinical progress in its partnered programmes with US generics maker Mylan.
The Biocon/Mylan partnership now has global phase III clinical trials ongoing for candidate biosimilars of adalimumab, bevacizumab, pegfilgrastim and trastuzumab. Two global clinical trials for their candidate biosimilar insulin glargine initiated in 2014, have also made significant progress. The patient recruitment for the Type-1 diabetes study has been completed ahead of schedule, while the recruitment for the Type-2 diabetes study is expected to be completed by July 2015. Meanwhile, rival Indian drugmaker Intas Pharmaceuticals (Intas) launched its ‘similar biologic’ of etanercept (Intacept) in India in March 2015. The company says this is the 'first biosimilar' of Amgen’s Enbrel (etanercept). Etanercept is indicated for rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis and plaque psoriasis, all debilitating autoimmune diseases. Intas expects, through the introduction of Intacept, to be able to reduce the cost of treatment for patients to about half that of the imported Enbrel.
Editor’s comment
Related article Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing. Copyright – Unless otherwise stated all contents of this website are © 2015 Pro Pharma Communications International. All Rights Reserved.
It should be noted that ‘similar biologics’ approved in India might not have been authorized following as strict a regulatory process as is required for approval of biosimilars in the European Union. The EMA (European Medicines Agency) regulatory requirements ensure the same high standards of quality, safety and efficacy for biosimilars as for originator biologicals, and also include a rigorous comparability exercise with the reference product.
Mylan and Biocon to partner on biosimilar insulin products
Source: Biocon, Intas
Comments (0)
Generics News Research General
- WHO prequalifies antiparasitic APIGenerics/General | Posted 06/12/2019
- EMA recommends approval for two new genericsGenerics/News | Posted 06/12/2019
- FDA generics approvals increasing but not for a...Generics/Research | Posted 29/11/2019
- FDA identifies causes of drug shortages, recomm...Generics/General | Posted 22/11/2019
Biosimilars News Research General
- WHO launches insulin prequalification programmeBiosimilars/General | Posted 29/11/2019
- Biosimilars of etanerceptBiosimilars/General | Posted 20/06/2014
- Biosimilars of ranibizumabBiosimilars/General | Posted 30/10/2015
- Australia approves five biosimilars since June...Biosimilars/News | Posted 06/12/2019